세계의 광학 전임상 이미징 시장

Global Optical Preclinical Imaging Market to Reach US$936.9 Million by 2030

The global market for Optical Preclinical Imaging estimated at US$627.4 Million in the year 2023, is expected to reach US$936.9 Million by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Bioluminescence / Fluorescence Imaging Systems, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$536.9 Million by the end of the analysis period. Growth in the Standalone Fluorescence Imaging Systems segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$164.0 Million While China is Forecast to Grow at 9.2% CAGR

The Optical Preclinical Imaging market in the U.S. is estimated at US$164.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$220.7 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Optical Preclinical Imaging Market - Key Trends & Drivers Summarized

How Has Optical Preclinical Imaging Transformed Biomedical Research?

Optical preclinical imaging has emerged as a transformative tool in biomedical research, enabling scientists to visualize cellular and molecular processes in live animal models with unprecedented detail. Traditionally, researchers relied on invasive methods to observe disease progression and treatment efficacy, but advancements in optical imaging technology have revolutionized preclinical studies by offering non-invasive, real-time insights. Techniques such as fluorescence and bioluminescence imaging allow researchers to monitor biological changes at cellular and subcellular levels, facilitating a deeper understanding of complex biological mechanisms. This capability is especially valuable in cancer research, where optical imaging can track tumor growth, metastasis, and responses to therapies without the need for multiple invasive procedures. By allowing researchers to conduct longitudinal studies on the same subject, optical imaging minimizes the number of animals required for experiments, which aligns with ethical considerations in biomedical research.

In addition to enhancing cancer research, optical preclinical imaging has advanced studies in immunology, neuroscience, and infectious diseases. The ability to visualize immune cell behavior and pathogen-host interactions in real-time provides critical data that can drive new therapeutic discoveries. For example, fluorescence imaging can track immune cells as they respond to infections or tumors, providing insights into how immune responses could be modulated to improve treatment outcomes. Similarly, optical imaging techniques are instrumental in neuroscience research, where they are used to monitor neural activity and brain function. By visualizing how neurons communicate or degenerate in disease models, researchers can better understand neurodegenerative diseases like Alzheimer’s and Parkinson’s, paving the way for targeted therapies. Thus, optical preclinical imaging has established itself as an indispensable tool for advancing our understanding of a wide array of medical conditions, positioning it at the forefront of modern biomedical research.

Moreover, the development of multimodal imaging systems, which combine optical imaging with other imaging techniques such as MRI or CT, has further extended the capabilities of preclinical studies. These systems provide complementary data that enhance the accuracy and depth of biological insights. For instance, while optical imaging offers high sensitivity for detecting specific biomarkers, CT and MRI add structural information that contextualizes those findings within the anatomical framework of the subject. This integration of functional and anatomical data enables researchers to build a more comprehensive picture of disease progression and therapeutic impact. With multimodal imaging, optical preclinical imaging is entering new realms of sophistication, solidifying its role as a pivotal technology for translational research aimed at bridging the gap between preclinical findings and clinical applications.

What Makes Optical Imaging a Preferred Technique in Drug Development?

Optical preclinical imaging has become a preferred technique in drug development, allowing pharmaceutical companies to evaluate the efficacy, distribution, and safety of drug candidates in vivo with high sensitivity. This non-invasive technique offers a faster and more cost-effective method for drug discovery and preclinical testing, significantly reducing the time it takes to bring new treatments from the laboratory to clinical trials. In fluorescence and bioluminescence imaging, drugs or biological markers are tagged with specific fluorescent or luminescent probes that emit light when interacting with target cells or proteins. These signals provide real-time information on how drugs interact with specific biological targets, making it easier to assess therapeutic effectiveness and identify potential side effects. With optical imaging, researchers can quickly screen multiple drug candidates, streamline the selection of promising compounds, and refine dosage and delivery methods before moving into costly clinical stages.

Furthermore, optical imaging is instrumental in pharmacokinetics and pharmacodynamics studies, which track how drugs move through and affect the body. By using fluorescent markers, scientists can visualize drug absorption, distribution, metabolism, and excretion (ADME) processes within living organisms. This data is essential for determining optimal dosing regimens and understanding how a drug's chemical properties impact its bioavailability and efficacy. Optical imaging's real-time feedback is especially valuable in understanding the behavior of biologics, such as antibodies and gene therapies, which often require precise targeting and monitoring. In addition, optical imaging can measure drug biodistribution at specific sites within the body, helping researchers determine if a drug effectively reaches its intended target without accumulating in non-targeted organs, which could lead to toxicity. This level of detail is difficult to achieve with other imaging techniques, highlighting the unique advantages of optical imaging in drug development.

The flexibility of optical preclinical imaging to work across various disease models, including cancer, infectious diseases, and metabolic disorders, has made it an essential tool in translational research. Optical imaging enables pharmaceutical companies to conduct rigorous testing of drug candidates in a wide range of pathological models, often using genetically modified organisms that express specific markers relevant to the disease being studied. For instance, researchers studying metabolic disorders can use optical imaging to observe changes in glucose uptake or lipid metabolism in real-time, providing valuable insights into the therapeutic effects of new drugs. This adaptability of optical imaging across disease models and research goals underscores its vital role in the drug development pipeline, empowering researchers to make data-driven decisions that accelerate the discovery of effective and safe treatments.

How Is Optical Preclinical Imaging Advancing Precision Medicine?

The field of precision medicine, which aims to customize treatments based on individual patient characteristics, has greatly benefited from advancements in optical preclinical imaging. By providing highly detailed molecular and cellular insights, optical imaging enables researchers to understand the underlying mechanisms of diseases at a personalized level, which is essential for developing targeted therapies. This capability is particularly valuable in oncology, where the heterogeneity of tumors means that different patients respond to treatments differently. With optical imaging, researchers can analyze the molecular profile of tumors in live models, identifying biomarkers that indicate which patients may respond to specific therapies. This precision-driven approach allows for the customization of treatment plans, maximizing therapeutic outcomes while minimizing unnecessary side effects, which is the core objective of precision medicine.

Optical imaging also plays a critical role in understanding genetic factors that influence disease susceptibility and treatment responses. In gene-editing studies, for example, fluorescent markers can be used to track the effects of gene modifications in real-time, showing how certain genetic alterations impact disease progression or drug efficacy. This allows researchers to explore potential gene therapies and assess the safety and effectiveness of CRISPR-based treatments. Additionally, optical imaging can visualize how specific genetic mutations affect cellular pathways, enabling scientists to identify potential therapeutic targets for rare and complex diseases. This level of insight is essential for advancing precision medicine, where the goal is to tailor treatments based on a patient’s unique genetic profile and disease characteristics.

In the realm of immunotherapy, optical preclinical imaging has opened up new possibilities for developing personalized cancer treatments that harness the body’s immune system to fight tumors. Optical imaging techniques, such as bioluminescence imaging, allow researchers to observe immune cell interactions with tumors, providing valuable data on how immunotherapies perform within a living organism. By tracking the movement and activity of immune cells, researchers can identify which types of immune cells are most effective in targeting specific tumor types and monitor how tumors evade immune responses. This information is crucial for designing more effective immunotherapies tailored to individual patients' immune profiles, aligning with the goals of precision medicine. Through its ability to reveal intricate biological mechanisms, optical preclinical imaging is not only advancing the development of personalized treatments but also helping to unravel the complex interactions between genetics, immunity, and disease.

What Is Fueling the Growth in the Optical Preclinical Imaging Market?

The growth in the optical preclinical imaging market is driven by several factors, including advancements in imaging technology, increased investment in drug discovery, and the rise of precision medicine. The demand for more accurate, non-invasive, and cost-effective imaging techniques in preclinical studies has fueled innovation in optical imaging systems, particularly in fluorescence, bioluminescence, and multimodal imaging. These technologies allow researchers to conduct highly detailed studies on disease mechanisms, drug efficacy, and biomarker expression, providing critical data that drive both academic research and pharmaceutical development. The accessibility and sensitivity of optical imaging, combined with its ability to deliver real-time feedback, make it a valuable tool for preclinical studies, which continue to expand as drug development becomes more complex and data-driven. This need for sophisticated imaging solutions in drug discovery and disease research is a key factor propelling the optical preclinical imaging market forward.

Another significant driver is the increasing emphasis on precision medicine, where optical preclinical imaging is essential for developing targeted therapies based on individual patient profiles. As precision medicine seeks to understand diseases at a molecular level, optical imaging provides the tools necessary to study cellular and genetic processes within disease models, enabling researchers to identify biomarkers and tailor therapies accordingly. The ability to visualize and quantify biomarker activity in live models aligns with the goals of precision medicine, making optical imaging indispensable for translating preclinical findings into personalized treatments. The ongoing shift toward precision medicine in both research and clinical practice has spurred growth in optical imaging technologies, as researchers require tools that can facilitate data collection and analysis on an individual level, ultimately helping to create more effective and personalized treatment options.

Furthermore, the growing focus on minimally invasive techniques in preclinical research is driving the adoption of optical imaging, as it allows for longitudinal studies with reduced animal usage and improved data consistency. Optical imaging’s non-invasive nature is particularly valuable for conducting repeated measures on the same subject, reducing the need for large sample sizes and aligning with ethical standards in animal research. Pharmaceutical companies and academic institutions are increasingly adopting these methods to optimize their preclinical studies, as optical imaging reduces costs and enhances experimental efficiency. With continued support for ethical research practices and the need for efficient drug development pipelines, the demand for optical preclinical imaging solutions is expected to rise steadily, supporting advancements in biomedical research and driving the growth of the optical imaging market.

SCOPE OF STUDY:

The report analyzes the Optical Preclinical Imaging market in terms of US$ Thousand by the following End-Use; Modality, and Geographic Regions/Countries:

Segments:

Modality (Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems, Optical + X-Ray / Optical + CT); End-Use (Pharma & Biotech Companies, Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• BioTek Instruments, Inc.
• Bruker Corporation
• Fujifilm Holdings America Corporation
• Fujifilm Holdings Corporation
• Magnetic Insight, Inc.
• MBF Bioscience
• Mediso Ltd.
• MILabs B.V.
• Miltenyi Biotec
• MR Solutions
• PerkinElmer, Inc.
• TriFoil Imaging
• UVP
• Vieworks Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Global Economic Update
  • Optical Preclinical Imaging - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advancements in Molecular Imaging Techniques Drive Adoption of Optical Preclinical Imaging
  • Increased R&D Expenditure in Biotechnology Propels Demand for Preclinical Imaging
  • Rising Demand for Cancer Research Boosts the Need for Optical Imaging
  • Technological Advancements in Fluorescence Imaging Sets the Stage for Market Growth
  • Government Funding for Biomedical Research Strengthens the Optical Imaging Market
  • Expanding Drug Discovery Programs Drive Growth in Optical Preclinical Imaging
  • Innovations in Imaging Agents Propel Demand for Optical Imaging
  • Advancements in 3D Imaging Drive Demand for Optical Preclinical Solutions
  • Increasing Use of Imaging in Stem Cell Research Strengthens Market Growth
  • Use of Optical Imaging for Neurodegenerative Disease Research Expands Opportunities
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 10: World Optical Preclinical Imaging Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Optical Preclinical Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Bioluminescence / Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Bioluminescence / Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Bioluminescence / Fluorescence Imaging Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Standalone Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Standalone Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Standalone Fluorescence Imaging Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Optical + X-Ray / Optical + CT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Optical + X-Ray / Optical + CT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Optical + X-Ray / Optical + CT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• JAPAN
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Japan 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• CHINA
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 41: China Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: China 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• EUROPE
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Europe 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Optical Preclinical Imaging by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• FRANCE
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: France 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 59: France Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• GERMANY
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: Germany 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: Italy 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: UK 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 77: UK Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 80: Spain Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Spain Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: Spain 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 86: Russia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Russia Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Russia 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Rest of Europe 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Optical Preclinical Imaging by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 107: Australia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Australia Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: Australia 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Australia Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 112: Australia 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• INDIA
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 113: India Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 114: India Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 115: India 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 116: India Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 117: India Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 118: India 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 119: South Korea Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 120: South Korea Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 121: South Korea 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 123: South Korea Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 124: South Korea 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Rest of Asia-Pacific Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 131: Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Latin America Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 133: Latin America 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Optical Preclinical Imaging by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 136: Latin America 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 140: Argentina Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Argentina Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 142: Argentina 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 143: Argentina Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Argentina Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 145: Argentina 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 146: Brazil Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Brazil Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 148: Brazil 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 149: Brazil Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Brazil Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 151: Brazil 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 152: Mexico Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Mexico Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 154: Mexico 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 155: Mexico Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Mexico Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 157: Mexico 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Rest of Latin America Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 160: Rest of Latin America 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Rest of Latin America Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 163: Rest of Latin America 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 164: Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Middle East Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 166: Middle East 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Optical Preclinical Imaging by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 169: Middle East 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 173: Iran Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Iran Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 175: Iran 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 176: Iran Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Iran Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 178: Iran 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 179: Israel Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Israel Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 181: Israel 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 182: Israel Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Israel Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 184: Israel 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Saudi Arabia Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 187: Saudi Arabia 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Saudi Arabia Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 190: Saudi Arabia 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 191: UAE Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 192: UAE Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 193: UAE 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 194: UAE Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 195: UAE Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 196: UAE 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Rest of Middle East Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 199: Rest of Middle East 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Rest of Middle East Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 202: Rest of Middle East 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• AFRICA
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 203: Africa Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Africa Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 205: Africa 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 206: Africa Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Africa Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 208: Africa 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030

IV. COMPETITION